Oppenheimer Lifts Boston Scientific (BSX) PT to $118 Following Strong Q2 Results

Boston Scientific Corporation (NYSE:BSX) is one of the most profitable growth stocks to buy according to billionaires. On July 24, Oppenheimer raised its price target for Boston Scientific from $110 to $118, while maintaining a Perform rating on the shares. The adjustment followed the release of the company’s Q2 2025 financial results.

In Q2, Boston Scientific generated a revenue of ~$5.1 billion, which was a 22.8% increase year-over-year. Adjusted EPS for the quarter was $0.75, compared to $0.62 in Q2 2024. The company’s Cardiovascular division saw the strongest growth with a 26.8% increase in net sales, while the MedSurg segment grew by 15.7%.

Boston Scientific also received US FDA approval for its FARAPULSE Pulsed Field Ablation/PF System to treat symptomatic persistent atrial fibrillation. It also commenced enrollment in the ReMATCH IDE clinical trial for its FARAWAVE and FARAPOINT PFA Catheters. Internationally, the company received CE mark approval for its WATCHMAN FLX Pro Left Atrial Appendage Closure Device.

Boston Scientific Corporation (NYSE:BSX) develops, manufactures, and markets medical devices for use in various interventional medical specialties. It has two segments: MedSurg and Cardiovascular.

While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.